Investors Encouraged to Join ESSA Pharma Securities Fraud Class Action Lawsuit

ESSA Pharma Securities Fraud Lawsuit

The Schall Law Firm, a well-known national firm specializing in shareholder rights litigation, is issuing a reminder to all investors concerning a class action lawsuit against ESSA Pharma Inc. (NASDAQ: EPIX). This lawsuit pertains to alleged violations of the Securities Exchange Act of 1934, specifically under sections 10(b) and 20(a), along with Rule 10b-5, which were established by the U.S. Securities and Exchange Commission (SEC).

The relevant period for potential claimants spans from December 12, 2023, through October 31, 2024. Investors who acquired ESSA's securities during this time and experienced losses are strongly encouraged to reach out to the Schall Law Firm before the deadline on March 25, 2025.

Why Join the Lawsuit?

The alleged misconduct by ESSA Pharma includes making false and misleading statements that significantly affected their stock price and misled investors about the effectiveness of its treatment regimen, specifically concerning the drug masofaniten. The complaint asserts that the combination of masofaniten and enzalutamide did not provide the supposed enhanced efficacy over enzalutamide alone. In fact, it revealed a lesser effectiveness in dealing with prostate cancer than previously claimed by the company.

As the truth behind these claims came to light, investors found themselves suffering substantial financial damage due to the misleading nature of ESSA's public disclosures. Therefore, affected shareholders now have an opportunity to recover their losses through this class action lawsuit.

Participation Details

Shareholders suffering losses during the specified Class Period should consider participating in the legal action. To gain representation in this case, contact Brian Schall of the Schall Law Firm for a free consultation. The firm's office is located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, or reach them by phone at 310-301-3335. More information is available via their website at www.schallfirm.com or by email at contact@schallfirm.com.

It's important to note that the class action has yet to be certified, meaning that until the certification occurs, your legal rights are not formally represented. Investors choosing not to act will remain absent class members and may forfeit any chance of recovery.

Conclusion

The securities fraud claims against ESSA Pharma could be a significant opportunity for impacted investors to seek redress for their losses. With the Schall Law Firm's experience in securities class action lawsuits, they aim to guide investors through the complexities of this legal process. Don't miss the chance to secure your rights as an investor in this ongoing situation.

For further details and to join the class action, ensure to get in touch with the Schall Law Firm promptly, as the window for participation will close soon.